OrbusNeich stent may be a safer option for patients with increased bleeding risk

HONG KONG – OrbusNeich has announced the publication of a case report demonstrating that revascularization with the Genous Stent may enable the safe and early discontinuation of dual antiplatelet therapy (DAPT) for challenging patients with an increased risk of bleeding, particularly during the procedure.

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The case study*, published in BMJ online, features a patient with chronic immune thrombocytopenic purpura (ITP) who was diagnosed with unstable angina due to a critical stenosis (90%) at the ostium of the left anterior descending (LAD) artery and a 75% stenosis of the proximal LAD artery. It was intended that the patient, who was treated with two Genous Stents, receive only one month of DAPT following the procedure. However, due to extensive bruising in the patient's forearm from antiplatelet use, the initial one month of DAPT was stopped after three days and restarted one week later when the ecchymosis was resolving. At 12-month follow-up, the patient remained asymptomatic.

"Chronic ITP is characterized by premature destruction of autoantibody-coated platelets causing persistent thrombocytopenia and increased risk of bleeding," said Charles Chan, M.D., Gleneagles Medical Center, Singapore.

"Additionally, ITP patients may also have an increased risk of thrombosis versus the general population and those patients with acquired thrombocytopenia. The Genous Stent has been shown to be safe and effective in high-risk patients with ST-segment elevation acute myocardial infarction (STEAMI) and has not been associated with increased rates of late stent thrombosis wheNike Air Max 90 Candy Drip